GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (FRA:AX9) » Definitions » E10

Akebia Therapeutics (FRA:AX9) E10 : €0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Akebia Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.083. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-14), Akebia Therapeutics's current stock price is €1.092. Akebia Therapeutics's E10 for the quarter that ended in Mar. 2024 was €0.00. Akebia Therapeutics's Shiller PE Ratio of today is .


Akebia Therapeutics E10 Historical Data

The historical data trend for Akebia Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics E10 Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -6.77 -7.36

Akebia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.73 -7.32 -7.45 -7.36 -

Competitive Comparison of Akebia Therapeutics's E10

For the Biotechnology subindustry, Akebia Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Shiller PE Ratio falls into.



Akebia Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.083/129.4194*129.4194
=-0.083

Current CPI (Mar. 2024) = 129.4194.

Akebia Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.287 100.560 -0.369
201409 -0.365 100.428 -0.470
201412 0.097 99.070 0.127
201503 -0.490 99.621 -0.637
201506 -0.356 100.684 -0.458
201509 -0.606 100.392 -0.781
201512 -0.615 99.792 -0.798
201603 -0.629 100.470 -0.810
201606 -0.846 101.688 -1.077
201609 -0.855 101.861 -1.086
201612 -0.939 101.863 -1.193
201703 -1.075 102.862 -1.353
201706 -0.472 103.349 -0.591
201709 -0.411 104.136 -0.511
201712 0.355 104.011 0.442
201803 -0.389 105.290 -0.478
201806 -0.514 106.317 -0.626
201809 -0.394 106.507 -0.479
201812 -0.665 105.998 -0.812
201903 -0.549 107.251 -0.662
201906 -0.434 108.070 -0.520
201909 -0.418 108.329 -0.499
201912 -0.711 108.420 -0.849
202003 -0.425 108.902 -0.505
202006 -1.137 108.767 -1.353
202009 -0.357 109.815 -0.421
202012 -0.493 109.897 -0.581
202103 -0.378 111.754 -0.438
202106 -0.423 114.631 -0.478
202109 -0.289 115.734 -0.323
202112 -0.354 117.630 -0.389
202203 -0.318 121.301 -0.339
202206 0.142 125.017 0.147
202209 -0.293 125.227 -0.303
202212 -0.038 125.222 -0.039
202303 -0.140 127.348 -0.142
202306 -0.055 128.729 -0.055
202309 -0.075 129.860 -0.075
202312 0.003 129.419 0.003
202403 -0.083 129.419 -0.083

Add all the adjusted EPS together and divide 10 will get our e10.


Akebia Therapeutics  (FRA:AX9) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Akebia Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (FRA:AX9) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (FRA:AX9) Headlines

No Headlines